H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
Saved in:
| Title: | H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours. |
|---|---|
| Authors: | Dibitetto D; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. diego.dibitetto@marionegri.it.; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, via Mario Negri 2, 20156, Milan, Italy. diego.dibitetto@marionegri.it., Liptay M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Vivalda F; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Dogan H; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Gogola E; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., González Fernández M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Duarte A; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Schmid JA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Decollogny M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Francica P; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Przetocka S; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Durant ST; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Forment JV; DDR Biology, Bioscience, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, UK., Klebic I; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Siffert M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., de Bruijn R; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands., Kousholt AN; Oncode Institute, Amsterdam, The Netherlands.; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Marti NA; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland., Dettwiler M; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Sørensen CS; Biotech Research and Innovation Centre, University of Copenhagen, 2200 N, Copenhagen, Denmark., Tille JC; Division of Clinical Pathology, Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Undurraga M; Division of Gynecology, Department of Pediatrics and Gynecology, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Labidi-Galy I; Faculty of Medicine, Department of Medicine and Center of Translational Research in Onco-Hematology, University of Geneva, Swiss Cancer Center Leman, Geneva, Switzerland.; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Lopes M; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Sartori AA; Institute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland., Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. j.jonkers@nki.nl.; Oncode Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl., Rottenberg S; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Cancer Therapy Resistance Cluster and Bern Center for Precision Medicine, Department for Biomedical Research, University of Bern, 3012, Bern, Switzerland. sven.rottenberg@unibe.ch.; Division of Molecular Pathology, The Netherlands Cancer Institute, 1066CX, Amsterdam, The Netherlands. sven.rottenberg@unibe.ch. |
| Source: | Nature communications [Nat Commun] 2024 May 24; Vol. 15 (1), pp. 4430. Date of Electronic Publication: 2024 May 24. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-48715-1 |
